Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
Dyadic International (NASDAQ:DYAI), a global biotechnology company specializing in precision engineered functional input proteins, has announced a proposed underwritten public offering of common stock. The offering will be managed by Craig-Hallum Capital Group LLC as the sole underwriter.
The company plans to use the proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement.
Dyadic International (NASDAQ:DYAI), un'azienda biotecnologica globale specializzata in proteine funzionali di precisione, ha annunciato una offerta pubblica garantita di azioni ordinarie. L'offerta sar脿 gestita da Craig-Hallum Capital Group LLC come unico sottoscrittore.
L'azienda prevede di utilizzare i proventi per capitale circolante e scopi aziendali generali, inclusi sviluppo prodotto, vendite e marketing. L'offerta viene effettuata in base a una dichiarazione di registrazione a scaffale efficace sul modulo S-3 depositata presso la SEC. I termini finali dell'offerta saranno resi noti in un supplemento al prospetto finale.
Dyadic International (NASDAQ:DYAI), una empresa biotecnol贸gica global especializada en prote铆nas funcionales de precisi贸n, ha anunciado una oferta p煤blica garantizada de acciones comunes. La oferta ser谩 gestionada por Craig-Hallum Capital Group LLC como 煤nico suscriptor.
La compa帽铆a planea usar los ingresos para capital de trabajo y prop贸sitos corporativos generales, incluyendo desarrollo de productos, ventas y marketing. La oferta se realiza conforme a una declaraci贸n de registro en estanter铆a efectiva en el Formulario S-3 presentada ante la SEC. Los t茅rminos finales de la oferta se revelar谩n en un suplemento final del prospecto.
Dyadic International (NASDAQ:DYAI)電� 鞝曤皜 靹り硠霅� 旮半姤靹� 雼氨歆堨潉 鞝勲鞙茧 頃橂姅 旮�搿滊矊 靸濍獏瓿淀暀 須岇偓搿�, 氤挫霅� 瓿店皽 欤检嫕 氚滍枆鞚� 鞝滌晥頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 氚滍枆鞚� Craig-Hallum Capital Group LLC臧� 雼弲 鞚胳垬鞚胳溂搿滌劀 甏�毽暕雼堧嫟.
須岇偓電� 靾橃澋旮堨潉 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄頃� 瓿勴殟鞚措┌, 鞐赴鞐愲姅 鞝滍拡 臧滊皽, 鞓侅梾 氚� 毵堨紑韺呾澊 韽暔霅╇媹雼�. 鞚措矆 氚滍枆鞚� SEC鞐� 鞝滌稖霅� 鞙犿毃頃� S-3 霌彪 氇呾劯靹滌棎 霐半澕 鞚措（鞏挫雼堧嫟. 氚滍枆鞚� 斓滌 臁瓣贝鞚� 斓滌 韴瀽靹る獏靹� 氤挫订鞛愲鞐愳劀 瓿店皽霅� 鞓堨爼鞛呺媹雼�.
Dyadic International (NASDAQ:DYAI), une soci茅t茅 biotechnologique mondiale sp茅cialis茅e dans les prot茅ines fonctionnelles de pr茅cision, a annonc茅 une offre publique garantie d'actions ordinaires. L'offre sera g茅r茅e par Craig-Hallum Capital Group LLC en tant que seul souscripteur.
La soci茅t茅 pr茅voit d'utiliser les fonds pour le fonds de roulement et des fins g茅n茅rales d'entreprise, y compris le d茅veloppement de produits, les ventes et le marketing. L'offre est r茅alis茅e conform茅ment 脿 une d茅claration d'enregistrement sur 茅tag猫re efficace sur le formulaire S-3 d茅pos茅e aupr猫s de la SEC. Les conditions finales de l'offre seront divulgu茅es dans un suppl茅ment final au prospectus.
Dyadic International (NASDAQ:DYAI), ein globales Biotechnologieunternehmen, das sich auf pr盲zise entwickelte funktionale Input-Proteine spezialisiert hat, hat ein vorgeschlagenes garantiertes 枚ffentliches Angebot von Stammaktien bekanntgegeben. Das Angebot wird von Craig-Hallum Capital Group LLC als alleinigem Underwriter verwaltet.
Das Unternehmen plant, die Erl枚se f眉r Umlaufverm枚gen und allgemeine Unternehmenszwecke zu verwenden, einschlie脽lich Produktentwicklung, Vertrieb und Marketing. Das Angebot erfolgt gem盲脽 einer wirksamen Shelf-Registrierungserkl盲rung auf Formular S-3, die bei der SEC eingereicht wurde. Die endg眉ltigen Bedingungen des Angebots werden in einem endg眉ltigen Prospekterg盲nzungsblatt bekannt gegeben.
- Potential to strengthen working capital position
- Funds to support product development and marketing initiatives
- Potential dilution for existing shareholders
- Uncertainty regarding the final size and terms of the offering
Insights
Dyadic announces public stock offering to raise capital, likely diluting current shareholders while funding operations and development.
Dyadic International (DYAI) has announced a proposed public offering of common stock with Craig-Hallum Capital Group as the sole underwriter. This equity raise signals potential dilution for existing shareholders, as the company issues new shares to raise capital. While the precise offering size and terms remain undisclosed, the capital infusion aims to strengthen Dyadic's financial position.
The company intends to use proceeds for working capital and general corporate purposes, specifically mentioning product development and sales/marketing initiatives. This suggests Dyadic requires additional funding to support ongoing operations and growth strategies in its biotechnology business focused on precision engineered functional input proteins.
The offering is being conducted through an existing S-3 shelf registration that was filed last August, indicating the company had anticipated potential capital needs and positioned itself to access markets when deemed necessary. Notably, the press release contains standard cautionary language emphasizing the offering remains subject to market conditions with no guarantee of completion, suggesting some flexibility in timing or potential to withdraw if market conditions deteriorate.
For investors, this offering represents a typical growth-stage biotech financing event, where dilution is accepted as necessary to fund the company's development pipeline and commercialization efforts in their specialized field of gene expression platforms for protein production.
JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (鈥淒yadic鈥� or the 鈥淐ompany鈥�) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the offering.
Dyadic intends to use the net proceeds from the proposed offering for working capital and general corporate purposes, such as product development, sales and marketing.
The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the聽Securities and Exchange Commission聽(鈥淪EC鈥�) on聽August 9, 2023聽and declared effective by the聽SEC聽on聽August 25, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting the SEC鈥檚 website at聽聽or by contacting Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets,聽323 N. Washington Ave, Suite 300, Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the聽SEC.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic鈥檚 C1 and Dapibus鈩� expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that relate to our current expectations and views of future events. All statements other than statements of historical facts contained in this press release, including statements regarding the completion and use of proceeds from the proposed offering, are forward-looking statements. These statements represent our opinions, expectations, beliefs, intentions, estimates or strategies regarding the future, which may not be realized. In some cases, you can identify forward-looking statements by terms such as 鈥渂elieve,鈥� 鈥渕ay,鈥� 鈥渆stimate,鈥� 鈥渃ontinue,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渟hould,鈥� 鈥減lan,鈥� 鈥渆xpect,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥渃ould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渙ngoing,鈥� 鈥渇uture鈥� or the negative of these terms or other similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements involve known and unknown risks, uncertainties, contingencies, changes in circumstances that are difficult to predict and other important factors that may cause our actual results, performance or achievements to be materially and/or significantly different from any future results, performance or achievements expressed or implied by the forward-looking statement. These risks, uncertainties, contingencies, and changes in circumstances relate to, among other things, to fluctuations in our share price, changes in market conditions and satisfaction of customary closing conditions related to the proposed public offering. Our actual results, performance, or achievements, including our ability to conduct and complete a public offering of our common stock on terms acceptable to us or at all, could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors. Such factors include the uncertainties, contingencies, and changes in circumstances discussed under the heading 鈥淩isk Factors鈥� in our annual report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 26, 2025, and our other filings with the SEC as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Dyadic disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
Contact:
Dyadic Applied BioSolutions
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
贰尘补颈濒:听
FAQ
What is the purpose of Dyadic International's (DYAI) public offering in July 2025?
Who is the underwriter for Dyadic's (DYAI) 2025 stock offering?
How can investors access information about Dyadic's (DYAI) stock offering?
What is the expected size of Dyadic International's (DYAI) 2025 stock offering?
When was Dyadic's (DYAI) shelf registration statement declared effective?
